{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:10:16Z","timestamp":1792444216376,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T00:00:00Z","timestamp":1665705600000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["NCT02414854"],"award-info":[{"award-number":["NCT02414854"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.rmed.2022.106938","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T02:18:23Z","timestamp":1660184303000},"page":"106938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline"],"prefix":"10.1016","volume":"202","author":[{"given":"Arnaud","family":"Bourdin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Christian","family":"Virchow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Papi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Njira L.","family":"Lugogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7294-4188","authenticated-orcid":false,"given":"Martti","family":"Antila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2009-4406","authenticated-orcid":false,"given":"David M.G.","family":"Halpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Daizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Djandji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6950-5582","authenticated-orcid":false,"given":"Benjamin","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juby A.","family":"Jacob-Nara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Gall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamo","family":"Deniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Rowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.rmed.2022.106938_bib1","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-018-8712-1","article-title":"Understanding asthma phenotypes, endotypes, and mechanisms of disease","volume":"56","author":"Kuruvilla","year":"2019","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"8","key":"10.1016\/j.rmed.2022.106938_bib2","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.200401-033OC","article-title":"Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study","volume":"170","author":"Bateman","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.rmed.2022.106938_bib3","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3109\/02770900903518835","article-title":"Factors associated with the control of severe asthma","volume":"47","author":"Hermosa","year":"2010","journal-title":"J. Asthma"},{"issue":"2","key":"10.1016\/j.rmed.2022.106938_bib4","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/thoraxjnl-2017-210531","article-title":"Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population","volume":"73","author":"Kerkhof","year":"2018","journal-title":"Thorax"},{"issue":"12","key":"10.1016\/j.rmed.2022.106938_bib5","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1164\/rccm.201810-1868CI","article-title":"Inhaled corticosteroid therapy in adult asthma. Time for a new therapeutic dose terminology","volume":"199","author":"Beasley","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"Supplement 86","key":"10.1016\/j.rmed.2022.106938_bib6","article-title":"Allergic rhinitis and its impact on asthma (ARIA) 2008","volume":"63","author":"Bousquet","year":"2008","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.rmed.2022.106938_bib7","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1084\/jem.20052448","article-title":"Type 2 immunity is controlled by IL-4\/IL-13 expression in hematopoietic non-eosinophilic cells of the innate immune system","volume":"203","author":"Voehringer","year":"2006","journal-title":"J. Exp. Med."},{"issue":"14","key":"10.1016\/j.rmed.2022.106938_bib8","doi-asserted-by":"crossref","first-page":"5147","DOI":"10.1073\/pnas.1323896111","article-title":"Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genes","volume":"111","author":"MacDonald","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"14","key":"10.1016\/j.rmed.2022.106938_bib9","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1073\/pnas.1324022111","article-title":"Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice","volume":"111","author":"Murphy","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.rmed.2022.106938_bib10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expet Rev. Clin. Immunol."},{"issue":"5","key":"10.1016\/j.rmed.2022.106938_bib11","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/all.14151","article-title":"Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation","volume":"75","author":"Le Floc'h","year":"2020","journal-title":"Allergy"},{"issue":"26","key":"10.1016\/j.rmed.2022.106938_bib12","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2022.106938_bib13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/all.14611","article-title":"Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline","volume":"76","author":"Bourdin","year":"2021","journal-title":"Allergy"},{"issue":"2","key":"10.1016\/j.rmed.2022.106938_bib14","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody for the treatment of sever allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"2","key":"10.1016\/j.rmed.2022.106938_bib15","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jaip.2019.08.050","article-title":"Dupilumab efficacy in patients with uncontrolled, moderate-to-severe allergic asthma","volume":"8","author":"Corren","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"156","key":"10.1016\/j.rmed.2022.106938_bib16","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0137-2019","article-title":"Minimal clinically important difference for asthma endpoints: an expert consensus report","volume":"29","author":"Bonini","year":"2020","journal-title":"Eur. Respir. Rev."},{"issue":"5","key":"10.1016\/j.rmed.2022.106938_bib17","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1183\/09031936.05.00035205","article-title":"Interpretative strategies for lung function tests","volume":"26","author":"Pellegrino","year":"2005","journal-title":"Eur. Respir. J."},{"issue":"26","key":"10.1016\/j.rmed.2022.106938_bib18","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.rmed.2022.106938_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nri3786","article-title":"Type 2 inflammation in asthma\u2014present in most, absent in many","volume":"15","author":"Fahy","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.rmed.2022.106938_bib20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/thoraxjnl-2018-212233","article-title":"Impact of an increase in the inhaled corticosteroid dose on blood eosinophils in asthma","volume":"74","author":"Lommatzsch","year":"2019","journal-title":"Thorax"},{"issue":"10056","key":"10.1016\/j.rmed.2022.106938_bib21","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/j.rmed.2022.106938_bib22","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.rmed.2022.106938_bib23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.rmed.2022.106938_bib24","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.rmed.2022.106938_bib25","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir. Med."},{"issue":"13","key":"10.1016\/j.rmed.2022.106938_bib26","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"9842","key":"10.1016\/j.rmed.2022.106938_bib27","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.rmed.2022.106938_bib28","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"19","key":"10.1016\/j.rmed.2022.106938_bib29","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.rmed.2022.106938_bib30","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1586\/ers.11.34","article-title":"Asthma-related comorbidities","volume":"5","author":"Boulet","year":"2011","journal-title":"Expet Rev. Respir. Med."},{"issue":"2","key":"10.1016\/j.rmed.2022.106938_bib31","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jaci.2013.04.052","article-title":"Severe adult-onset asthma: a distinct phenotype","volume":"132","author":"Amelink","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.rmed.2022.106938_bib32","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1183\/09031936.05.00037905","article-title":"Risk factors of frequent exacerbations in difficult-to-treat asthma","volume":"26","author":"ten Brinke","year":"2005","journal-title":"Eur. Respir. J."},{"issue":"12","key":"10.1016\/j.rmed.2022.106938_bib34","doi-asserted-by":"crossref","first-page":"E72","DOI":"10.1002\/lary.24305","article-title":"Cytokine correlation between sinus tissue and nasal secretions among chronic rhinosinusitis and controls","volume":"123","author":"Oyer","year":"2013","journal-title":"Laryngoscope"},{"issue":"9","key":"10.1016\/j.rmed.2022.106938_bib35","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/all.12440","article-title":"Association between group 2 innate lymphoid cells enrichment, nasal polyps and allergy in chronic rhinosinusitis","volume":"69","author":"Miljkovic","year":"2014","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.rmed.2022.106938_bib36","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jaip.2016.11.007","article-title":"Identifying risk of future asthma attacks using UK medical record data: a respiratory effectiveness group initiative","volume":"5","author":"Blakey","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"4","key":"10.1016\/j.rmed.2022.106938_bib37","doi-asserted-by":"crossref","first-page":"420","DOI":"10.4193\/Rhino09.095","article-title":"Comparative clinical and airway inflammatory features of asthmatics with or without polyps","volume":"48","author":"Bilodeau","year":"2010","journal-title":"Rhinology"},{"key":"10.1016\/j.rmed.2022.106938_bib38","author":"Global Initiative for Asthma"},{"issue":"1","key":"10.1016\/j.rmed.2022.106938_bib39","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaci.2017.12.1009","article-title":"Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids","volume":"143","author":"Peters","year":"2019","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611122002037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611122002037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T01:41:39Z","timestamp":1727746899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611122002037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":38,"alternative-id":["S0954611122002037"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2022.106938","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dupilumab efficacy in subgroups of type 2 asthma with high-dose inhaled corticosteroids at baseline","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2022.106938","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106938"}}